When evaluating whether a company is worth investing in, it is not enough to look only at its current industry-leading position. More importantly, one must determine whether it can maintain that position over the long term. If a company currently dominates but faces competitors that can easily catch up or even surpass it, its profitability may come under threat—a major warning sign for investors.
Therefore, one of the first steps in analyzing a company is to examine its competitive advantages, or its “moat.” Just as a castle’s surrounding moat can fend off enemies, a company’s moat protects it from competitive attacks. Moats can arise from strong brands, multiple patents, hard-to-replicate distribution networks, and more. A solid moat helps a company sustain its market position, thereby supporting long-term profit growth. When combined with financial strength and a focus on innovation, such stocks offer excellent investment value. The following are three healthcare stocks with the most durable competitive moats.
Eli Lilly is the manufacturer of one of the hottest pharmaceutical products today—weight-loss drugs. The company sells tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, though doctors often prescribe both for weight-loss indications. Additionally, Lilly recently received approval for an oral weight-loss drug, Foundayo.
These drugs belong to the GLP-1 class, which has garnered significant attention in recent years due to surging demand. They act on digestive-related hormones, thereby helping to control appetite and blood sugar levels. These medications are typically self-administered once a week, are convenient to use, and are safe and effective—Foundayo is a daily oral tablet. Eli Lilly’s relationships with prescribing physicians and its reputation among satisfied patients are key competitive advantages. Furthermore, patent protection for tirzepatide extends at least through 2036.
Vertex is the global leader in cystic fibrosis drugs and has expanded its portfolio into other areas in recent years—last year launching a non-opioid drug for pain management. Its cystic fibrosis portfolio is a powerful profit engine and also constitutes a solid moat. Vertex’s patent protection extends at least through the end of the 2030s, and the company continues to innovate in the cystic fibrosis space, meaning its leading position may last even longer.
Currently, Vertex’s CFTR modulators can treat approximately 90% of cystic fibrosis patients—because the disease is linked to genetic mutations, no single drug works for all patients. However, Vertex is developing an mRNA therapy in collaboration with Moderna, aiming to treat the 5,000 patients who cannot use existing drugs. If all goes well, Vertex is expected to achieve full coverage of the entire cystic fibrosis patient population.
Intuitive Surgical is the world’s leading surgical robotics company, selling the da Vinci series of surgical robots, which are widely used in common procedures such as hernia repairs and gallbladder surgeries. Over the years, its installed base of robots and the number of surgical procedures using them have continued to grow.
Two factors keep Intuitive ahead: First, surgical robots are expensive, typically costing over $1 million each. This means that once a hospital or health system purchases one, it is likely to continue using the equipment to amortize its investment. Second, most surgeons are trained on the da Vinci system and are therefore familiar with this platform. Surgeons will naturally choose the system they know rather than switching to a completely different device. These two factors create an extremely strong moat for Intuitive, making it one of the most durable moats in the healthcare industry.
Summary: The three healthcare stocks above—Eli Lilly, Vertex Pharmaceuticals, and Intuitive Surgical—have established the most enduring competitive moats in their respective industries through brand and patent protection, technological monopoly in a rare disease field, and high switching costs combined with surgeon usage habits, respectively. These moats not only help them maintain market leadership but also provide solid support for long-term profit growth, making them key companies worth paying close attention to when investors select targets in the healthcare sector.
